Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

perations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information please visit www.us.boehringer-ingelheim.com

About Presidio in Hepatitis C Virus (HCV) 
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company focused on the discovery and development of oral pan-genotypic therapeutics for HCV patients.  Efforts are currently focused on novel inhibitors of both the HCV NS5A and NS5B genes. PPI-668 is an investigational, pan-genotypic, once daily, NS5A inhibitor. In earlier clinical studies in healthy volunteers and HCV-infected patients, PPI-668 has been well-tolerated to date with no serious or severe adverse events and no apparent pattern of treatment-related clinical side effects or laboratory abnormalities. PPI-668 achieves plasma concentrations high enough to inhibit most pre-existing resistant variants and achieves steady-state levels after a single dose. In a clinical study of PPI-668 monotherapy in GT1 HCV-infected patients, viral load reductions of 3.5 to 3.7 log10 HCV were achieved in 1-2 days. Activity was also noted in GT3a HCV-infected patients.

Presidio's NS5B inhibitor, PPI-383, is a novel pan-genotypic non-nucleoside inhibitor with potential to inhibit all of the major HCV genotypes. This compound is currently in Phase 1 studies in healthy subjects.  For more information, please visit our website at: www.presidiopharma.com

Contact:
Boehringer Ingelheim Pharmaceuticals, Inc.
Name: Susanne Granold
Public Relations
Phone: 203-791-5851
Email: Susanne.Granol
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing ... today announced that James A. Joyce , Aethlon ... overview at the 27th Annual ROTH Conference on March ... previously scheduled to present at 5:30 pm Pacific on ... at The Ritz-Carlton Hotel in Laguna Niguel, ...
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical ... a conference call on Friday, March 13, 2015 ... of operations for the fourth quarter and full ... held and currently makes certain financial information available ... Securities and Exchange Commission and will make certain ...
(Date:3/6/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... payment from Biogen Idec related to advancing the ongoing ... infants with spinal muscular atrophy (SMA).  ... is a randomized, double-blind, sham-procedure controlled thirteen month study ... will evaluate the efficacy and safety of a 12 ...
Breaking Medicine Technology:Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5
... PARSIPPANY, N.J., Jan. 11 Survival of the fittest? ... not only what you know today, but what you need ... Whoever has the right insight and accurate forecasting skills will ... (and growing) market in the world, its sheer size also ...
... Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: DYSC), a ... of information from content publishers to enterprise customers and their constituents, ... the website of DDN ( Drug Discovery News ). ... is titled "Speeding the Path to FDA Approval in the Era ...
Cached Medicine Technology:Elite Pharma Insiders to Reveal Key Survival Strategies for Pharmaceutical Industry in 2010 2Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 ... of “Women’s Health,” a campaign that seeks to educate, ... role when it comes to their health and their ... the rise, it has never been more pertinent to ... rights. , The print component of “Women’s Health” ...
(Date:3/6/2015)... March 06, 2015 As healthcare ... images and content from disparate systems, they are ... care and increase efficiency. Enterprise content management ... content with core IT solutions, including electronic medical ... existing IT applications. , The following organizations ...
(Date:3/6/2015)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Mallory Sofastaii, a mobile ... and shared with viewers how this is a fully immersive ... mobile games have benefited from building in a social media ... to connect their games to Facebook, see what level their ...
(Date:3/6/2015)... Saving Moses, a global humanitarian organization ... traveling to Angola, Africa March 7-14 to visit malnutrition ... , This will be the organizations fifth time to ... commitment to the region’s population by saving infants and ... with the mothers and babies of the malnutrition program, ...
(Date:3/6/2015)... 2015 Ticket Down is a reputable source ... at the Moda Center. After being away from the ... showing no signs of letting up on his “Garth Brooks ... his wife, Trisha Yearwood, to venues around the United States. ... critically acclaimed tour to the Moda Center in Portland, OR. ...
Breaking Medicine News(10 mins):Health News:The Well-Woman: Encouraging Regular Screenings and Advocating for Women’s Health Rights with Mediaplanet’s “Women’s Health” Campaign 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3
... Curative ... Therapy Driving Growth, ARCADIA, Calif., Oct. 3 ... Program for Los Angeles, a,ranking of the 50 fastest growing technology, ... Touche USA LLP, one,of the nation,s leading professional services organizations. Rankings ...
... CHICAGO, Oct. 3 President Bush,s veto today,of ... for millions of,children from families with low incomes ... dental health, says Oral Health America, a national,advocacy ... ten million children eligible for coverage through a,bipartisan, ...
... Citys infant mortality rate widely regarded as a barometer ... the Health Department reported today. The rate in 2006 was ... the previous year. The City has made major progress in ... was double what it is today, but the decline has ...
... faculty has received a five-year, $8.4 million grant from ... to survey the genetic, physical and behavioral profiles of ... the reach and ethnic diversity of the Autism Genetic ... research, overseen by Clara Lajonchere, research assistant professor at ...
... WASHINGTON, Oct. 3 The United States,Conference of ... H.,Palmer, today expressed shock and disbelief at President Bush,s ... Insurance Program known as,SCHIP. With his action, 10 million ... protection., "We are extremely disappointed because this is ...
... The California Nurses,Association/National Nurses Organizing Committee today condemned ... Children,s Health Insurance,Program. "Listening to the overheated rhetoric ... Rove may be gone but his legacy lives on," ... Presidents. She chastised,Bush for his recent claims that legislators ...
Cached Medicine News:Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 2Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 4Health News:SCHIP Veto a Big Cavity for Children's Oral Healthcare, Advocates Say 2Health News:New York City's infant mortality rate declined in 2006 2Health News:New York City's infant mortality rate declined in 2006 3Health News:New York City's infant mortality rate declined in 2006 4Health News:USC granted $8.4 million for autism research 2Health News:USC granted $8.4 million for autism research 3Health News:Mayors Express Frustration Over President Bush's Veto to SCHIP Legislation 2Health News:California Nurses Association Blasts Bush for Veto on Children's Health 2
... The CA-1000 counts a Petri dish in ... the optical characteristics of the colonies as ... CA-1000 is equipped with three types of ... lighter or darker than the agar and ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
... sophisticated whole blood analysis system that is ... satisfying the stringent requirements of the central ... all of the components of a traditional ... sampling unit, all of the sensors and ...
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
Medicine Products: